• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

快感缺失预示着心理社会功能不佳:来自全科医生治疗的一大群重度抑郁症患者的结果。

Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners.

作者信息

Vinckier F, Gourion D, Mouchabac S

机构信息

Service de psychiatrie, faculté de médecine, centre hospitalier Sainte-Anne, université Paris Descartes, Sorbonne Paris Cité, 75014 Paris, France; Motivation, brain, and behavior lab, institut du cerveau et de la moelle épinière, groupe hospitalier Pitié-Salpêtrière, 75013 Paris, France.

17, rue des Marronniers, 75016 Paris, France.

出版信息

Eur Psychiatry. 2017 Jul;44:1-8. doi: 10.1016/j.eurpsy.2017.02.485. Epub 2017 Mar 8.

DOI:10.1016/j.eurpsy.2017.02.485
PMID:28535406
Abstract

BACKGROUND

Anhedonia is a core symptom of major depression and a key prognostic factor that is often poorly explored in clinical trials of major depressive disorder (MDD). Beyond symptomatic remission, psychosocial functioning also reveals difficulty in achieving remission in patients with MDD. The main objective of this study was to explore the interrelationships between social functioning and anhedonia on a longitudinal basis.

METHODS

In total, 1570 outpatients treated for MDD with agomelatine were included. Severity of depression and levels of anhedonia and of psychosocial functioning were assessed at inclusion and at 10-14 weeks, with specific standardized scales (MADRS, QFS, SHAPS, CGI). Multivariate regression and mediation analyses were performed.

RESULTS

Using multivariate regression, we showed that improvement of anhedonia was the strongest predictor of improvement in psychosocial functioning (odds ratio=7.3 [4.3-12.1] P<0.0001). In addition, mediation tests confirmed that the association between improvement of depressive symptoms and improvement of social functioning was significantly underpinned by the improvement of anhedonia over time. Finally, we explored the determinants of the dissociation of the response, i.e., the persistence of psychosocial dysfunctioning despite a symptomatic response to antidepressant treatment, which remains a widespread situation in clinical practice. We showed that this dissociation was strongly predicted by persistence of anhedonia.

CONCLUSION

Our results suggest that anhedonia is one of the strongest predictors of psychosocial functioning, along with symptomatic remission, and should be carefully assessed by health professionals, in order to optimize pharmacological as well as non-pharmacological management of depression.

摘要

背景

快感缺失是重度抑郁症的核心症状,也是一个关键的预后因素,但在重度抑郁症(MDD)的临床试验中常常未得到充分研究。除了症状缓解外,心理社会功能在MDD患者中也显示出难以实现缓解。本研究的主要目的是纵向探索社会功能与快感缺失之间的相互关系。

方法

总共纳入了1570名接受阿戈美拉汀治疗的MDD门诊患者。在入组时以及10 - 14周时,使用特定的标准化量表(MADRS、QFS、SHAPS、CGI)评估抑郁严重程度、快感缺失水平和心理社会功能水平。进行了多变量回归和中介分析。

结果

通过多变量回归,我们表明快感缺失的改善是心理社会功能改善的最强预测因素(优势比 = 7.3 [4.3 - 12.1],P < 0.0001)。此外,中介测试证实,随着时间的推移,快感缺失的改善显著支持了抑郁症状改善与社会功能改善之间的关联。最后,我们探索了反应解离的决定因素,即尽管对抗抑郁治疗有症状反应,但心理社会功能障碍仍然持续存在,这在临床实践中仍然是一种普遍情况。我们表明,这种解离强烈地由快感缺失的持续存在所预测。

结论

我们的结果表明,快感缺失是心理社会功能的最强预测因素之一,与症状缓解一样,健康专业人员应仔细评估,以便优化抑郁症的药物和非药物管理。

相似文献

1
Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners.快感缺失预示着心理社会功能不佳:来自全科医生治疗的一大群重度抑郁症患者的结果。
Eur Psychiatry. 2017 Jul;44:1-8. doi: 10.1016/j.eurpsy.2017.02.485. Epub 2017 Mar 8.
2
Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.阿戈美拉汀治疗对重度抑郁症患者C反应蛋白水平的影响:一项“真实世界”日常临床实践中的探索性研究。
CNS Spectr. 2017 Aug;22(4):342-347. doi: 10.1017/S1092852916000572. Epub 2016 Oct 5.
3
The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.去甲文拉法辛对患有重度抑郁症的在职门诊患者神经认知及工作功能的影响。
J Affect Disord. 2016 Oct;203:55-61. doi: 10.1016/j.jad.2016.05.074. Epub 2016 May 31.
4
The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.伏硫西汀对重度抑郁症患者快感缺失的疗效
Front Psychiatry. 2019 Jan 31;10:17. doi: 10.3389/fpsyt.2019.00017. eCollection 2019.
5
Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.使用氟西汀治疗重度抑郁症期间的心理社会功能
J Clin Psychopharmacol. 2004 Oct;24(5):507-11. doi: 10.1097/01.jcp.0000138761.85363.d5.
6
Clinical effectiveness: the importance of psychosocial functioning outcomes.临床疗效:心理社会功能结果的重要性。
J Affect Disord. 2011 Aug;132 Suppl 1:S9-S13. doi: 10.1016/j.jad.2011.03.046. Epub 2011 Apr 22.
7
Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.重性抑郁障碍的认知-功能关系:文拉法辛与艾司西酞普兰开放标签研究的关键数据来自乌克兰。
J Affect Disord. 2019 May 1;250:114-122. doi: 10.1016/j.jad.2019.03.040. Epub 2019 Mar 5.
8
Clinical predictors associated with full remission versus episode of major depressive disorder outpatients: the experience at a teaching hospital in Taiwan.与重度抑郁症门诊患者完全缓解与发作相关的临床预测因素:台湾一家教学医院的经验。
BMC Psychiatry. 2014 Sep 24;14:273. doi: 10.1186/s12888-014-0273-0.
9
Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.艾司西酞普兰与西酞普兰治疗重度抑郁症的疗效及耐受性:一项针对成年门诊患者的为期6周的多中心、前瞻性、随机、双盲、活性药物对照研究。
Clin Ther. 2007 Nov;29(11):2319-32. doi: 10.1016/j.clinthera.2007.11.014.
10
Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients.首发重性抑郁障碍患者的早发性和晚发性抑郁在残留症状、功能和生活质量方面是否存在差异。
Asian J Psychiatr. 2020 Jan;47:101843. doi: 10.1016/j.ajp.2019.101843. Epub 2019 Oct 16.

引用本文的文献

1
A Narrative Review on Toxidromes in the Psychiatric Population: Implications for Overdose Prevention.精神科人群中毒综合征的叙述性综述:对预防药物过量的启示
J Clin Med. 2025 Aug 31;14(17):6160. doi: 10.3390/jcm14176160.
2
A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study.NBI-1065846(TAK-041)用于治疗与重度抑郁症相关的快感缺失患者的2期随机试验:TERPSIS研究结果
J Clin Psychopharmacol. 2025;45(5):432-440. doi: 10.1097/JCP.0000000000002046. Epub 2025 Jul 28.
3
Assessing social anhedonia in a transdiagnostic sample: Insights from a computational psychiatry lens.
在跨诊断样本中评估社交快感缺失:来自计算精神病学视角的见解。
J Mood Anxiety Disord. 2024 Sep 17;8:100088. doi: 10.1016/j.xjmad.2024.100088. eCollection 2024 Dec.
4
Association between anhedonia severity and clinical, humanistic, and economic outcomes among US adults with major depressive disorder.美国重度抑郁症成年患者中快感缺失严重程度与临床、人文及经济结局之间的关联
Int J Neuropsychopharmacol. 2025 Jul 2. doi: 10.1093/ijnp/pyaf048.
5
The impact of rumination and anhedonia on daily social and occupational function.沉思和快感缺乏对日常社交及职业功能的影响。
J Clin Exp Neuropsychol. 2025 Jul 1:1-14. doi: 10.1080/13803395.2025.2526650.
6
Childhood P300 predicts development of depressive disorders into adolescence.儿童期的P300可预测抑郁障碍发展至青少年期的情况。
Cogn Affect Behav Neurosci. 2025 Jul 1. doi: 10.3758/s13415-025-01327-8.
7
Neural activity to reward and loss predicting treatment outcomes for adults with generalized anxiety disorder: A randomized clinical trial.预测广泛性焦虑症成人治疗结果的奖励与损失相关神经活动:一项随机临床试验。
J Mood Anxiety Disord. 2025 Mar;9. doi: 10.1016/j.xjmad.2025.100107. Epub 2025 Jan 8.
8
Selective KOR antagonist alters functional patch sizes in individualized brain system: results from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).选择性κ阿片受体拮抗剂改变个体化脑系统中的功能性脑区大小:情绪和焦虑谱系障碍快速失败试验(FAST-MAS)的结果
Neuropsychopharmacology. 2025 May 13. doi: 10.1038/s41386-025-02125-z.
9
Hedonic capacity in a Chinese community population sample: psychometric properties of the dimensional anhedonia rating scale (DARS) and exploration of gender differences.中国社区人群样本中的享乐能力:维度性快感缺失评定量表(DARS)的心理测量特性及性别差异探索。
BMC Psychol. 2025 Apr 21;13(1):410. doi: 10.1186/s40359-025-02740-x.
10
Anhedonia as a Core Symptom of Depression and a Construct for Biological Research.快感缺失作为抑郁症的核心症状及生物学研究的一个概念
Focus (Am Psychiatr Publ). 2025 Apr;23(2):163-172. doi: 10.1176/appi.focus.20240050. Epub 2025 Apr 15.